ZAYNICH™ (cefepime and zidebactam)
ZAYNICH™ at a glance
Indicated for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible microorganisms.
-
Novel mechanism of action
Synergistically targets multiple penicillin-binding proteins (PBP1a/b, 2 and 3).
Watch and learn more -
Clinical efficacy
In the Phase 3 ENHANCE1 clinical trial, ZAYNICH™ demonstrated higher composite response of clinical cure and microbiologic eradication at the test of cure (89%) vs. meropenem (68.4%) for a treatment difference of 20.6%.
Review the results -
Safety
The most common adverse reactions occurring in ≥2% of patients receiving ZAYNICH™ were diarrhea, hypertension, headache, and hypokalemia.
See the safety profile
Explore ZAYNICH™
- Burden of anti-microbial resistance What AMR is, and the risks it carries for hospitalized patients.
- The Zaynich™ journey How ZAYNICH™ was discovered and developed.
- How Zaynich™ works Mechanism of action, microbiology, and surveillance data.
- Clinical data Efficacy and safety results from clinical trials.
References: 1. ZAYNICH (cefepime and zidebactam) US Prescribing Information. Wockhardt Bio AG; 2026. 2. Moya B, Barcelo IM, Bhagwat S, et al. WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent "β-lactam enhancer" activity against Pseudomonas aeruginosa, including multidrug-resistant metallo-β-lactamase-producing high-risk clones. Antimicrob Agents Chemother. 2017;61(6):e02529-16. doi:10.1128/AAC.02529-16 3. Rajavel M, Kumar V, Nguyen H, et al. Structural characterization of diazabicyclooctane β-lactam "enhancers" in complex with penicillin-binding proteins PBP2 and PBP3 of Pseudomonas aeruginosa. mBio. 2021;12(1):e03058-20. doi:10.1128/mBio.03058-20 4. Bhavsar S, Joshi S, Pawar S, et al. Structure activity relationship (SAR) driven design and discovery of WCK 5107 (zidebactam): novel β-lactam enhancer, potent against multidrug-resistant gram-negative pathogens. Med Chem Res. 2023;32(10):2245-2255. 5. Pan X, Zhao X, Song Y, et al. Molecular characterization of WCK 5222 (cefepime/zidebactam)-resistant mutants developed from a carbapenem-resistant Pseudomonas aeruginosa clinical isolate. Microbiol Spectr. 2022;10(1):e0267821. doi:10.1128/spectrum.02678-21.